HUTCHMED ANNOUNCES NMPA APPROVAL FOR ATLED® (FANREGRATINIB) FOR THE TREATMENT OF PATIENTS WITH FGFR2-FUSION/REARRANGEMENT INTRAHEPATIC CHOLANGIOCARCINOMA

Reuters · 4d ago

Please log in to view news